Pediatric Clinical Trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
This clinical trial is looking at brain function in young patients receiving methotrexate for acute lymphoblastic leukemia. Learning about the long-term effects of methotrexate on brain function may help doctors plan cancer treatment.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: laboratory biomarker analysis
- other: pharmacological study
- procedure: cognitive assessment
- procedure: diffusion tensor imaging
- procedure: psychosocial assessment and care
Eligibility
Inclusion Criteria:
- Diagnosis of acute lymphoblastic leukemia
- Enrolled on COG-AALL0434 (Cohort #1 only) or COG-AALL0232 (Cohorts #1 and #2)
- Patients must have received either high-dose methotrexate or escalating-dose
methotrexate during interim maintenance.
- No CNS-3 disease
- Patients must enroll within 8-24 months after completion of therapy on COG-AALL0232
and no evidence of relapsed or secondary malignancy
- No known significant neurodevelopmental disability unrelated to cancer diagnosis
including, but not limited to, any of the following:
- Down syndrome
- Fragile X mental retardation
- Autism
- Pervasive developmental disability
- Seizure disorder
- Attention-deficit hyperactivity disorder or specific learning disability (e.g.,
dyslexia) allowed
- No sensory impairment (e.g., pre-existing uncorrectable vision impairment or deafness)
- No cranial radiation therapy
Ages Eligible for Study
1 Year - 17 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Pediatric Hematology/Oncology
650-723-5535
Not Recruiting